Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab

Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Peng-Yu, Li, Zi-Yun, Cai, Sui-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435079/
https://www.ncbi.nlm.nih.gov/pubmed/37600791
http://dx.doi.org/10.3389/fimmu.2023.1188523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435079/
https://www.ncbi.nlm.nih.gov/pubmed/37600791
http://dx.doi.org/10.3389/fimmu.2023.1188523

Ejemplares similares